LIPO

2.86

0.35% 0.010

Pre-mercato: 2.80 -0.06 -2.10%

Lipella Pharmaceuticals Inc (LIPO)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$2.85

Aprire:

$2.86

Volume 24 ore:

19,055

Relative Volume:

0.10

Capitalizzazione di mercato:

$3.46M

Reddito:

Utile/perdita netta:

$-4.74M

Rapporto P/E:

-3.8133

EPS:

-0.75

Flusso di cassa netto:

$-3.46M

1 W Prestazione:

-6.11%

1M Prestazione:

+9.58%

6M Prestazione:

-21.79%

1 anno Prestazione:

-62.76%

Intervallo 1D:

$2.85

$2.92

Intervallo di 1 settimana:

$2.80

$3.15

Portata 52W:

$2.21

$12.00

Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile

Nome

Lipella Pharmaceuticals Inc

Settore

Healthcare (1176)

Industria

Biotechnology (685)

Telefono

412-901-0315

Indirizzo

400 N LEXINGTON ST, PITTSBURGH

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

LIPO's Discussions on Twitter

Confronta LIPO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
LIPO Lipella Pharmaceuticals Inc	2.86	3.46M	0	-4.74M	-3.46M	-0.75
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Lipella Pharmaceuticals Inc Borsa (LIPO) Ultime notizie

Jan 20, 2025

Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World

Jan 20, 2025

Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World

Jan 20, 2025

Jan 17, 2025

LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 - MSN

Jan 17, 2025

Jan 13, 2025

Lipella Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com South Africa

Jan 13, 2025

Lipella Pharmaceuticals faces potential Nasdaq delisting - Investing.com

Jan 13, 2025

Jan 10, 2025

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - The Manila Times

Jan 10, 2025

Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire

Jan 10, 2025

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement - GlobeNewswire Inc.

Jan 10, 2025

Jan 07, 2025

Lipella Pharmaceuticals Inc. Announces Second Closing of Offering 2024 - Defense World

Jan 07, 2025

Jan 03, 2025

SABBY MANAGEMENT, LLC Acquires 60,325 Shares in Lipella Pharmace - GuruFocus.com

Jan 03, 2025

Jan 02, 2025

Lipella Pharmaceuticals Inc. Enters into Agreement with Spartan Capital Securities, LLC and Closes Initial OfferingThe pharmaceutical company Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) recently disclosed in an 8-K filing with the U.S. Securities and - Defense World

Jan 02, 2025

Dec 30, 2024

Lipella Pharmaceuticals Cancels Special Meeting Due to Lack of Quorum - Defense World

Dec 30, 2024

Dec 19, 2024

Lipella Pharmaceuticals Inc. announced that it has received $1.722 million in funding - Marketscreener.com

Dec 19, 2024

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - The Manila Times

Dec 19, 2024

Dec 12, 2024

Lipella Pharmaceuticals Enters into Placement Agent and Consulting Agreements - Defense World

Dec 12, 2024

Dec 10, 2024

Lipella Pharmaceuticals Inc. announced that it expects to receive $6 million in funding - Marketscreener.com

Dec 10, 2024

Dec 06, 2024

Lipella Pharmaceuticals reschedules special meeting - Investing.com

Dec 06, 2024

Lipella Pharmaceuticals reschedules special meeting By Investing.com - Investing.com Canada

Dec 06, 2024

Dec 03, 2024

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus - GlobeNewswire

Dec 03, 2024

Lipella Pharmaceuticals Advances Novel Oral Treatment in Phase 2a Trial, Details Published in CUREUS - StockTitan

Dec 03, 2024

Nov 28, 2024

Critical Review: Lipella Pharmaceuticals (LIPO) & Its Peers - Defense World

Nov 28, 2024

Nov 27, 2024

Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail

Nov 27, 2024

Nov 24, 2024

Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN

Nov 24, 2024

Nov 21, 2024

Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire

Nov 21, 2024

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - GlobeNewswire

Nov 21, 2024

Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan

Nov 21, 2024

Nov 20, 2024

Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN

Nov 20, 2024

Nov 17, 2024

Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com

Nov 15, 2024